NASDAQ:LGND Ligand Pharmaceuticals Q2 2026 Earnings Report $316.24 -6.37 (-1.97%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$323.10 +6.86 (+2.17%) As of 07/10/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ligand Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $1.99Beat/MissN/AOne Year Ago EPSN/ALigand Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$62.93 millionBeat/MissN/AYoY Revenue GrowthN/ALigand Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Ligand Pharmaceuticals Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Mesoblast Limited (OtherMEOBF) and Cogstate Ltd (OtherCOGZF)July 9 at 8:49 PM | theglobeandmail.comStifel Nicolaus Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceJuly 9 at 3:18 AM | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 11 at 1:00 AM | Porter & Company (Ad)Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty TrustJune 30, 2026 | seekingalpha.comLigand Announces Closing of Convertible Senior Notes OfferingJune 25, 2026 | globenewswire.comLigand Pharmaceuticals Rises After Upsized Convertible Notes Pricing and Buyback PlanJune 23, 2026 | quiverquant.comQSee More Ligand Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ligand Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your email. Email Address About Ligand PharmaceuticalsLigand Pharmaceuticals (NASDAQ:LGND), Inc. is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas. The company’s product offerings center around several core platforms. Captisol® is a chemically modified cyclodextrin used to improve the solubility, stability and delivery of small-molecule drug candidates. Ligand’s research services portfolio includes antibody discovery and optimization through its OmniAb™ platform, as well as absorption, distribution, metabolism and excretion (ADME) testing services provided by its Cyprotex and Absorption Systems subsidiaries. Together, these technologies and services support early- and late-stage drug development programs for a broad range of partners worldwide. Founded in 1987 and headquartered in San Diego, California, Ligand has grown through strategic acquisitions and collaborations, establishing a global footprint that spans North America, Europe and Asia. The company’s leadership team is led by President and Chief Executive Officer John L. Higgins, whose experience in drug development and corporate transactions has guided Ligand’s transformation into a technology-focused partner for the biopharmaceutical industry. Ligand continues to seek new alliances and in-licensing opportunities aimed at expanding its platform capabilities and royalty revenue streams.View Ligand Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Why WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real ProfitLockheed Martin Secures the Ultimate Defense Moat Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
